Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRE | P78334 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 2/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909429 | 1.00 | GABRP (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17795736 | 0.90 | MGAM (0.38) | MGAMFUCA1 | |
| SCHEMBL17795737 | 0.90 | MGAM (0.38) | MGAMFUCA1 | |
| SCHEMBL941940 | 0.78 | MGAM (0.42) | MGAMFUCA1TDP1 | |
| SCHEMBL12909426 | 0.78 | MGAM (0.42) | MGAMFUCA1TDP1 | |
| SCHEMBL20225057 | 0.78 | MGAM (0.42) | MGAMFUCA1TDP1 | |
| SCHEMBL12945229 | 0.68 | MGAM (0.39) | MGAMFUCA1 | |
| SCHEMBL146088 | 0.60 | — | — | |
| SCHEMBL1354935 | 0.60 | GABRP (0.73) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18222603 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | GABRP 2059/4885GABRD 3882/4885GABRA1 3392/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | GABRP 2059/4885GABRD 3882/4885GABRA1 3392/4885 |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | IRS1, SLC2A1, INSR | GABRP 2059/4885GABRD 3882/4885GABRA1 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.